2-methyl-2,4,5,6-tetrahydro-cyclopentapyrazole | 84597-86-4

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 唑类
• 英文名称: 2-methyl-2,4,5,6-tetrahydro-cyclopentapyrazole
• 英文别名: 2-Methyl-2,4,5,6-tetrahydro-cyclopentapyrazol；2-methyl-5,6-dihydro-4H-cyclopenta[c]pyrazole
• CAS: 84597-86-4
• 化学式: C₇H₁₀N₂
• 分子量: 122.17
• InChiKey: UMXPHYRPFNMSBS-UHFFFAOYSA-N

物化性质

• 沸点：
  215.7±9.0 °C(Predicted)
• 密度：
  1.19±0.1 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  0.9
• 重原子数：
  9
• 可旋转键数：
  0
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.57
• 拓扑面积：
  17.8
• 氢给体数：
  0
• 氢受体数：
  1

反应信息

• 作为产物：
  描述：

  1,4,5,6-四氢环戊并吡唑-3-甲酸 在 sodium methylate 、 铜 作用下， 生成 2-methyl-2,4,5,6-tetrahydro-cyclopentapyrazole
  参考文献：
  名称：

  v. Auwers; Noll, Justus Liebigs Annalen der Chemie, 1938, vol. 536, p. 97,108

  摘要：

  DOI：

文献信息

• [EN] PYRROLIDINE AMIDE COMPOUNDS AS HISTONE DEMETHYLASE INHIBITORS<br/>[FR] COMPOSÉS DE PYRROLIDINE À UTILISER EN TANT QU'INHIBITEURS DE L'HISTONE DÉMÉTHYLASE
  申请人：GENENTECH INC

  公开号：WO2016057924A1

  公开（公告）日：2016-04-14

  The present invention relates to compounds of formula (I) useful as inhibitors of one or more histone demethylses, such as KDM5. The invention also provides pharmaceutically acceptable compositions comprising compounds of the present invention and the compounds for use in methods for the treatment of various disorders. Formula (I): or a salt thereof, wherein: A is selected from the group consisting of:

  本发明涉及公式（I）的化合物，用作一个或多个组蛋白去甲基化酶（如KDM5）的抑制剂。本发明还提供了包括本发明化合物的药学上可接受的组合物，并提供了用于治疗各种疾病的方法中使用的化合物。公式（I）：或其盐，其中：A选自以下组成的组中：
• [EN] FUNGICIDAL AMIDES<br/>[FR] AMIDES FONGICIDES
  申请人：DU PONT

  公开号：WO2014172190A1

  公开（公告）日：2014-10-23

  Disclosed are compounds of Formula 1, including all stereoisomers, N-oxides, and salts thereof, wherein A is a radical selected from the group consisting of A-1 through A-11, L is C(R12a)R12b-C(R13a)R13b; or 1,2-phenylene G is a radical selected from the group consisting of G-1, G-2, G-3, G-4, and G-5 and R1, R2, R12a, R12b, R13a, R13b and Q are as defined in the disclosure. Also disclosed are compositions containing the compounds of Formula 1 and methods for controlling plant disease caused by a fungal pathogen comprising applying an effective amount of a compound or a composition of the invention.1

  揭示了Formula 1的化合物，包括所有立体异构体、N-氧化物和盐，其中A是从A-1到A-11组成的基团中选择的基团，L是C(R12a)R12b-C(R13a)R13b；或1,2-苯基，G是从G-1、G-2、G-3、G-4和G-5组成的基团中选择的基团，R1、R2、R12a、R12b、R13a、R13b和Q如本公开中所定义。还揭示了含有Formula 1化合物的组合物以及用于控制由真菌病原体引起的植物疾病的方法，包括施用本发明的化合物或组合物的有效量。
• FUNGICIDAL AMIDES
  申请人：E. I. DU PONT DE NEMOURS AND COMPANY

  公开号：US20160081337A1

  公开（公告）日：2016-03-24

  Disclosed are compounds of Formula 1, including all stereoisomers, N-oxides, and salts thereof, wherein A is a radical selected from the group consisting of A-1 through A-11, L is —C(R 12a )R 12b —C(R 13a )R 13b —; or 1,2-phenylene G is a radical selected from the group consisting of and R 1 , R 2 , R 12a , R 12b , R 13a , R 13b and Q are as defined in the disclosure. Also disclosed are compositions containing the compounds of Formula 1 and methods for controlling plant disease caused by a fungal pathogen comprising applying an effective amount of a compound or a composition of the invention.

  本发明涉及化合物1的公开，包括所有立体异构体，N-氧化物和其盐，其中A是从A-1到A-11组成的基团，L是—C（R12a）R12b—C（R13a）R13b—；或1,2-苯基，G是从中选择的基团，包括R1，R2，R12a，R12b，R13a，R13b和Q的定义如本公开说明书所述。本发明还公开了含有化合物1的组合物以及控制由真菌病原体引起的植物病害的方法，包括施用本发明中化合物或组合物的有效量。
• [EN] N-(2-(4-CYANOTHIAZOLIDIN-3-YL)-2-OXOETHYL)- QUINOLINE-4-CARBOXAMIDES<br/>[FR] N-(2-(4-CYANOTHIAZOLIDIN-3-YL)-2-OXOÉTHYL)-QUINOLÉINE-4-CARBOXAMIDES
  申请人：ASTRAZENECA AB

  公开号：WO2022130270A1

  公开（公告）日：2022-06-23

  Compounds having the structure of Formula (I): and pharmaceutically acceptable salts thereof, wherein X1, R1, R2, R3, R4, R5and R6are as defined in the specification; pharmaceutical compositions comprising such compounds and salts; use of such compounds and salts to treat or prevent Prolyl endopeptidase fibroblast activation protein (FAP)-mediated conditions; kits comprising such compounds and salts; and methods for manufacturing such compounds and salts.

  具有公式（I）结构及其药学上可接受的盐的化合物，其中X1，R1，R2，R3，R4，R5和R6如规范中所定义; 包括此类化合物和盐的制药组合物; 使用此类化合物和盐来治疗或预防脯氨酰内切酶成纤维细胞激活蛋白（FAP）介导的疾病; 包含此类化合物和盐的试剂盒; 以及制造此类化合物和盐的方法。
• SUBSTITUIERTE IMIDAZOLYL-CARBOXAMIDE ALS SCHÄDLINGSBEKÄMPFUNGSMITTEL
  申请人：Bayer CropScience Aktiengesellschaft

  公开号：EP3414240B1

  公开（公告）日：2019-12-25